Wall Street analysts predict that Intrexon Corp (NYSE:XON) will post sales of $48.79 million for the current fiscal quarter, according to Zacks. Four analysts have issued estimates for Intrexon’s earnings. The highest sales estimate is $51.91 million and the lowest is $44.65 million. Intrexon posted sales of $46.00 million in the same quarter last year, which suggests a positive year-over-year growth rate of 6.1%. The business is scheduled to report its next quarterly earnings results on Wednesday, March 7th.

According to Zacks, analysts expect that Intrexon will report full year sales of $48.79 million for the current financial year, with estimates ranging from $197.50 million to $206.11 million. For the next fiscal year, analysts forecast that the company will post sales of $249.15 million per share, with estimates ranging from $217.00 million to $281.22 million. Zacks’ sales averages are an average based on a survey of sell-side analysts that that provide coverage for Intrexon.

Several equities research analysts have recently issued reports on the company. ValuEngine cut Intrexon from a “sell” rating to a “strong sell” rating in a report on Sunday, December 31st. Northland Securities reiterated a “buy” rating and issued a $27.00 price target on shares of Intrexon in a research report on Friday, October 6th. JMP Securities reiterated an “outperform” rating and issued a $42.00 price target on shares of Intrexon in a research report on Thursday, October 5th. Griffin Securities reiterated a “buy” rating and issued a $55.00 price target on shares of Intrexon in a research report on Friday, October 6th. Finally, Bank of America dropped their price target on Intrexon from $25.00 to $21.00 and set a “neutral” rating for the company in a research report on Friday, November 10th. Three investment analysts have rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average target price of $38.50.

Shares of Intrexon (NYSE:XON) opened at $13.15 on Friday. Intrexon has a twelve month low of $10.26 and a twelve month high of $26.99. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.05 and a quick ratio of 1.85. The stock has a market capitalization of $1,590.00, a PE ratio of -11.74 and a beta of 1.33.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Alliancebernstein L.P. grew its position in Intrexon by 0.6% in the second quarter. Alliancebernstein L.P. now owns 32,610 shares of the biotechnology company’s stock worth $786,000 after acquiring an additional 200 shares in the last quarter. Legal & General Group Plc grew its position in Intrexon by 2.1% in the second quarter. Legal & General Group Plc now owns 18,843 shares of the biotechnology company’s stock worth $454,000 after acquiring an additional 393 shares in the last quarter. State Board of Administration of Florida Retirement System grew its position in Intrexon by 2.1% in the second quarter. State Board of Administration of Florida Retirement System now owns 77,176 shares of the biotechnology company’s stock worth $1,859,000 after acquiring an additional 1,570 shares in the last quarter. Peloton Wealth Strategists grew its position in Intrexon by 6.8% in the second quarter. Peloton Wealth Strategists now owns 29,900 shares of the biotechnology company’s stock worth $720,000 after acquiring an additional 1,900 shares in the last quarter. Finally, Pacer Advisors Inc. grew its position in Intrexon by 26.3% in the second quarter. Pacer Advisors Inc. now owns 9,282 shares of the biotechnology company’s stock worth $224,000 after acquiring an additional 1,930 shares in the last quarter. Institutional investors own 77.45% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Intrexon Corp (XON) Expected to Announce Quarterly Sales of $48.79 Million” was first published by American Banking News and is the sole property of of American Banking News. If you are viewing this report on another website, it was stolen and reposted in violation of U.S. and international copyright law. The legal version of this report can be accessed at https://www.americanbankingnews.com/2018/01/06/intrexon-corp-xon-expected-to-announce-quarterly-sales-of-48-79-million.html.

Intrexon Company Profile

Intrexon Corporation (Intrexon) forms collaborations to create biologically-based products and processes using synthetic biology. The Company’s domestic operations are in California, Florida, Maryland, and Virginia, and its primary international operations are in Belgium and Hungary. The Company designs, builds and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components.

Get a free copy of the Zacks research report on Intrexon (XON)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Intrexon (NYSE:XON)

Receive News & Ratings for Intrexon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon and related companies with MarketBeat.com's FREE daily email newsletter.